Fluxion gains access to CCG’s HTS core to generate large, high-resolution datasets that accelerate commercialization of FDA-aligned predictive tools in ion channel analytics.

The collaboration combines Fluxion’s AI-driven analytics with CCG’s high-throughput screening infrastructure to create omics-scale datasets and standardize interpretation of automated patch-clamp data.

Fluxion CEO Eli Black says the collaboration aligns predictive analytics with regulatory trends to reduce pre-clinical toxicology costs and time while boosting ML model power.

Fluxion Therapeutics specializes in AI-driven pre-clinical assay development and large-scale electrophysiology data handling, complemented by the University of Michigan's Center for Chemical Genomics (CCG), which provides HTS, assay optimization, and pharmacology expertise to accelerate therapeutics from basic biology to novel treatments.

Strategic benefit for CCG includes access to AI tools that convert raw electrophysiology data into actionable insights, enhancing Target ID and Hit ID in neurological and metabolic diseases.

A primary focus of the collaboration is refining Fluxion’s E-Profiler assay platform and validating new models using CCG’s chemical libraries, with aims including CiPA-compliant cardiotoxicity prediction, expanded DILI and immunotoxicity toxicology, and integration of electrophysiology data with other omics via Physiomics.

The partnership seeks to advance safety and toxicology by refining Fluxion’s E-Profiler platform and validating models for cardiotoxicity, DILI, and immunotoxicity, while integrating electrophysiological data with other omics layers through Physiomics.

CCG Director Andy Alt emphasizes that Fluxion’s AI-aided assays complement HTS to create a standardized, high-resolution platform that reduces analytics biases and expands ion channel research possibilities.

Overall, the collaboration aims to advance safety and toxicology modeling by combining AI-driven analytics, cardiotoxicity and immunotoxicity assessment, and integrative Physiomics approaches to accelerate drug development.

Fluxion and the University of Michigan’s Center for Chemical Genomics launched a two-year collaboration to develop AI and ML models for automated analysis of ion channel electrophysiology.